Momenta Pharmaceuticals, Inc. announced …

Momenta Pharmaceuticals, Inc. announced that the results of the M118 EMINENCE clinical trial have published in Circulation. The key conclusion in the paper is that in this study M118 was well-tolerated and provided further evidence of feasibility for use as an anticoagulant in patients undergoing elective percutaneous coronary intervention…. http://bit.ly/diW5I5